Conference call to discuss the strategic collaboration with Almirall

Stockholm, 12 December 2016. Nuevolution AB (publ) (NUE.ST) announce that the company’s executive management will host a conference call and webcast to discuss the strategic collaboration with Almirall on Monday 12 December at 14:00 CET. Access to the event can be obtained as follows:

LIVE access on Monday 12 December at 14:00 CET

Telephone numbers:
SE: +46 85 664 2690
DK: +45 3544 5575
UK: +44 20 3008 9802
US: +1 855 831 5945

Webcast will be available at www.nuevolution.com in the Investors section and at www.financialhearings.com.

REPLAY access

Webcast replay will be available at www.nuevolution.com in the Investors section and at www.financialhearings.com.

For more information, please contact:

Alex Haahr Gouliaev
Chief Executive Officer
Nuevolution AB (publ)
Phone: +45 7020 0987
Email: [email protected]

Henrik D. Simonsen
Chief Financial Officer
Nuevolution AB (publ)
Phone: +45 3913 0947
Email: [email protected]

About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the Securities Market Act. The information was sent for publication, through the agency of the contact persons set out above, on Monday 12 December 2016, 11:30 (CET).

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Redeye AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com